EMEA restructures

Article

Pharmaceutical Technology Europe

The EMEA unveiled several changes to the organization, including a new structure and visual identity.

The EMEA has unveiled several changes to the organization, including a new structure and visual identity.

One primary structural change involves integrating human pre- and post-authorization activities into one unit, “to guarantee seamless lifecycle-management of medicines,” according to a press statement. Also, a group will be dedicated to the management of product data and documentation to help improve the efficiency of data-management processes throughout the agency.

This is the second time the EMEA has undergone restructuring. Established in 1995, the agency’s “responsibilities and tasks have grown, giving it a stronger role in the protection of public and animal health in Europe,” according to the press statement. “All of this has been underpinned by the creation of additional scientific committees and advisory groups, which bring with them the need for enhanced coordination and support. Legislative proposals currently being considered by the European Parliament and Council are expected to bring further responsibilities to the Agency.”

As part of the agency’s new visual, or public, identity, the EMEA will launch a new website in the coming months. The site is expected to be easier for the public to use and designed to meet readers’ needs.

Going forth, the agency will now be known as the EMA as opposed to the EMEA.

www.emea.europa.eu

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content